AMPH
Amphastar Pharmaceuticals, Inc.
26.30$
+5.2%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -2.1% | +4.1% | -5.3% | +3.6% | +2.1% | +3.1% | -0.7% | +3.2% | -2.2% | +1.2% | +5.8% | |
| – | -9.8% | +13.4% | -13.0% | +13.1% | -2.2% | +10.1% | -1.2% | +10.1% | -0.5% | -0.4% | -0.4% | |
| – | -45.9% | +39.4% | -5.7% | +1.3% | -21.1% | +20.6% | +2.7% | +15.4% | -21.4% | +0.6% | +30.6% | |
| – | -14.4% | +12.8% | -24.8% | +15.0% | -11.5% | +6.9% | -2.2% | +20.2% | +1.5% | +4.1% | -1.4% | |
| – | -3.0% | +20.3% | -4.9% | +9.8% | -4.8% | +5.3% | -7.4% | +9.1% | -2.2% | +3.0% | -2.0% | |
| – | -3.8% | +9.1% | +6.0% | +6.5% | +18.0% | +20.6% | +3.4% | -3.0% | -4.9% | -3.8% | +5.7% | |
| – | +4.0% | -2.0% | -0.7% | +4.1% | -6.4% | +3.5% | +7.6% | +0.2% | -0.1% | -2.1% | +2.2% | |
| – | -1.0% | -1.0% | -1.0% | -1.0% | -0.7% | -1.1% | -1.1% | -1.1% | -1.1% | -1.1% | +1.1% | |
| – | -8.0% | +3.3% | -13.7% | +5.1% | +3.4% | +3.5% | -2.0% | +3.7% | -5.5% | +4.1% | +11.5% | |
| – | -12.6% | +13.2% | -46.3% | +16.1% | +9.3% | +14.6% | -11.4% | +16.3% | -22.9% | +4.0% | +60.0% | |
| – | +4.6% | +0.6% | -2.9% | +5.1% | +57.8% | +13.2% | +10.5% | -0.6% | +9.4% | +18.9% | -0.8% | |
| – | -20.4% | +43.6% | -13.0% | +7.3% | -10.5% | +73.1% | -20.7% | -3.2% | -19.6% | +8.9% | -18.5% | |
| – | -7.6% | +0.8% | -1.2% | +1.6% | +0.9% | +0.4% | +0.6% | +0.1% | +0.0% | +0.2% | 0.0% | |
| – | +7.4% | +5.2% | +6.1% | +2.0% | +0.6% | +2.6% | +0.8% | +2.5% | +1.6% | -2.0% | -0.7% | |
| – | +9.7% | +10.5% | +8.4% | +8.2% | +7.2% | +4.4% | +5.2% | +2.8% | +3.8% | +1.0% | +4.5% | |
| – | -1.7% | 0.0% | -1.8% | -0.4% | +0.4% | -4.2% | -3.5% | -0.9% | -1.1% | -1.5% | -4.8% |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.